Search research articles
Contact Us
Filters
Showing results (41-50 of 209) with videos related to
Page
of 21
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN
|
September 5, 2009
Mineralocorticoid receptor blockers and chronic kidney disease
Gaurav Jain, Ruth C Campbell, David G Warnock
The Journal of Biological Chemistry
|
January 26, 2002
Anionic phospholipids regulate native and expressed epithelial sodium channel (ENaC)
He-Ping Ma, Sunil Saxena, David G Warnock
Nephron
|
January 27, 2017
Risks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria
David G Warnock, Pierre Delanaye, Richard J Glassock
Journal of the American Society of Nephrology : JASN
|
July 28, 2007
Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta
Hindia Tahir, Leslie L Jackson, David G Warnock
Nature Reviews. Nephrology
|
December 13, 2016
The global burden of chronic kidney disease: estimates, variability and pitfalls
Richard J Glassock, David G Warnock, Pierre Delanaye
Seminars in Nephrology
|
November 23, 2014
Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels
Eric K Judd, David A Calhoun, David G Warnock
Clinical Journal of the American Society of Nephrology : CJASN
|
December 17, 2009
Enzyme replacement therapy and Fabry nephropathy
David G Warnock, Erica Daina, Giuseppe Remuzzi, et al.
Journal of the American Society of Nephrology : JASN
|
April 19, 2002
Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT(1) receptors
János Peti-Peterdi, David G Warnock, P Darwin Bell
American Journal of Nephrology
|
August 24, 2011
Chronic kidney disease and risk of death from infection
Henry E Wang, Christopher Gamboa, David G Warnock, et al.
Lancet (London, England)
|
May 4, 2010
Enzyme replacement therapy for Fabry's disease
Stephen Waldek, Dominique P Germain, Christoph Wanner, et al.
Page
of 21
Search research articles
Search
Showing results (41-50 of 209) with videos related to
Sort By:
Page
of 21
Clinical Journal of the American Society of Nephrology : CJASN
|
September 5, 2009
Mineralocorticoid receptor blockers and chronic kidney disease
Gaurav Jain, Ruth C Campbell, David G Warnock
The Journal of Biological Chemistry
|
January 26, 2002
Anionic phospholipids regulate native and expressed epithelial sodium channel (ENaC)
He-Ping Ma, Sunil Saxena, David G Warnock
Nephron
|
January 27, 2017
Risks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria
David G Warnock, Pierre Delanaye, Richard J Glassock
Journal of the American Society of Nephrology : JASN
|
July 28, 2007
Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta
Hindia Tahir, Leslie L Jackson, David G Warnock
Nature Reviews. Nephrology
|
December 13, 2016
The global burden of chronic kidney disease: estimates, variability and pitfalls
Richard J Glassock, David G Warnock, Pierre Delanaye
Seminars in Nephrology
|
November 23, 2014
Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels
Eric K Judd, David A Calhoun, David G Warnock
Clinical Journal of the American Society of Nephrology : CJASN
|
December 17, 2009
Enzyme replacement therapy and Fabry nephropathy
David G Warnock, Erica Daina, Giuseppe Remuzzi, et al.
Journal of the American Society of Nephrology : JASN
|
April 19, 2002
Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT(1) receptors
János Peti-Peterdi, David G Warnock, P Darwin Bell
American Journal of Nephrology
|
August 24, 2011
Chronic kidney disease and risk of death from infection
Henry E Wang, Christopher Gamboa, David G Warnock, et al.
Lancet (London, England)
|
May 4, 2010
Enzyme replacement therapy for Fabry's disease
Stephen Waldek, Dominique P Germain, Christoph Wanner, et al.
Page
of 21